Belvedere Trading’s Cue Biopharma CUE Stock Holding History

Belvedere Trading’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-757	Closed	-$277K	–	365
2021 Q1	$277K	Sell	757 -16	-2%	-$6.58K	0.02%	140
2020 Q4	$290K	Buy	+773	New	+$309K	0.01%	113

Other funds holding CUE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belvedere Trading's CUE Position: Q1 2022 in Review

Belvedere Trading sold out of Cue Biopharma (CUE) in Q1 2022, closing a stake of 661 shares — an estimated $178K sold.

Belvedere Trading first reported a position in CUE in Q4 2020 and held it in 3 quarters. The position peaked at $178K in Q4 2021. 100 funds tracked by Wall St. Rank hold CUE as of Q1 2022.

Belvedere Trading reported no remaining Cue Biopharma position as of Q1 2022 after selling out during the quarter.
Belvedere Trading sold 661 Cue Biopharma shares in Q1 2022, an estimated $178K.
Belvedere Trading first reported a position in Cue Biopharma in Q4 2020 and held it in 3 quarters.
Belvedere Trading's Cue Biopharma position peaked at $178K in Q4 2021.
100 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2022.

Based on Belvedere Trading's 13F filing for Q1 2022, filed 20 Apr 2022.